• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol.

作者信息

Grünwald Viktor, Ohlmann Carsten-Henning, Hadaschik Boris

机构信息

Interdisciplinary Genitourinary Oncology, Department of Urology and Department of Medical Oncology, University Hospital Essen, Essen, Germany.

Department of Urology, Johanniter Hospital Bonn, Bonn, Germany.

出版信息

Eur Urol. 2022 Jun;81(6):621. doi: 10.1016/j.eururo.2022.02.011. Epub 2022 Feb 19.

DOI:10.1016/j.eururo.2022.02.011
PMID:35193775
Abstract
摘要

相似文献

1
Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol.关于：醋酸阿比特龙和泼尼松龙联合或不联合恩杂鲁胺治疗高危非转移性前列腺癌：STAMPEDE平台方案两项随机对照3期试验主要结果的荟萃分析。
Eur Urol. 2022 Jun;81(6):621. doi: 10.1016/j.eururo.2022.02.011. Epub 2022 Feb 19.
2
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙和泼尼松与或不与恩扎卢胺用于高危非转移性前列腺癌：来自 STAMPEDE 平台方案两项随机对照 3 期试验主要结果的荟萃分析。
Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.
3
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙联合泼尼松或联合恩扎卢胺治疗开始去势治疗的转移性前列腺癌患者：STAMPEDE 平台方案两项随机 3 期试验的最终结果。
Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1.
4
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌患者后的雄激素信号靶向治疗的临床结局：COU-AA-302 的事后分析。
Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15.
5
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.化疗初治转移性去势抵抗性前列腺癌患者接受恩扎卢胺或醋酸阿比特龙治疗的生存结局。
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1032-1040. doi: 10.1038/s41391-021-00318-3. Epub 2021 Feb 21.
6
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.CARD 研究：卡巴他赛对比阿比特龙或恩杂鲁胺用于转移性去势抵抗性前列腺癌老年患者的疗效和安全性。
Eur Urol. 2021 Oct;80(4):497-506. doi: 10.1016/j.eururo.2021.06.021. Epub 2021 Jul 15.
7
Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.一线恩扎鲁胺与阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌（HEAT）患者的疲劳、生活质量和代谢变化：一项随机试验方案。
BMJ Open. 2019 Sep 11;9(9):e030218. doi: 10.1136/bmjopen-2019-030218.
8
Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).恩扎卢胺或醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌患者的疲劳、健康相关生活质量和代谢变化：一项随机临床试验（HEAT）。
Eur J Cancer. 2022 Aug;171:75-84. doi: 10.1016/j.ejca.2022.04.034. Epub 2022 Jun 13.
9
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.醋酸阿比特龙联合泼尼松或恩杂鲁胺对转移性去势抵抗性前列腺癌患者报告结局的影响：来自观察性AQUARiUS研究的最终12个月分析
Eur Urol. 2020 Mar;77(3):380-387. doi: 10.1016/j.eururo.2019.09.019. Epub 2019 Oct 5.
10
Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.关于：多西他赛治疗转移性去势抵抗性前列腺癌进展后持续使用恩杂鲁胺（PRESIDE）：一项国际随机3b期研究。
Eur Urol. 2023 Jul;84(1):141-142. doi: 10.1016/j.eururo.2023.02.021. Epub 2023 Mar 2.